Table 2.
MIS-C children’s clinical parameters of the study population.
| Male | Female | |
|---|---|---|
| Age median (years, IQR) | 5.8 (1–14) | 5.9 (1–14) |
| Gender n (%) | 35 (54%) | 30 (46%) |
| RT-PCR positive n (%) | 0 | 0 |
| Serology IgG positive n (%) | 35 (100%) | 30 (100%) |
| Underlying conditions n (%) | 3 (4.5%) | 1 (1.5%) |
| Co-existing infections n (%) | 4 (6%) | 1 (1.5%) |
| Median duration since proven or suspected COVID illness or contact (weeks, range) | 3 w (10 d–4 w) | 3 w (10 d–4 w) |
| COVID-19 symptoms n (%) | ||
| Fever | 35 (100%) | 30 (100%) |
| Gastrointestinal | 28 (80%) | 24 (80%) |
| Respiratory | 8 (23%) | 7 (23%) |
| Mucocutaneous | 27 (77%) | 22 (73%) |
| Asymptomatic | 0 | 0 |
| Cardiovascular symptoms/signs | ||
| Hypotension | 20 (57%) | 14 (47%) |
| Shock | 1 (2.9%) | 2 (6%) |
| Coronary artery dilatation | 3 (9%) | 2 (7%) |
| Myocardial dysfunction | 22 (63%) | 12 (40%) |
| Median duration of stay | 5 (3–18) | 4 (1–15) |
| Treatment n (%) | ||
| IVIG | 25 (71%) | 19 (63%) |
| Steroids | 24 (69%) | 23 (77%) |
| PICU admission | 19 (54%) | 15 (50%) |
| Antibiotics | 34 (97%) | 26 (87%) |
| Tocilizumab (8 mg/kg) | 2 (6%) | 1 (3%) |
| Respiratory support n (%) | ||
| Mechanical ventilation | 1 (3%) | 0 |
| HHFNC | 3 (9%) | 2 (7%) |
| Oxygen | 5 (14%) | 4 (13%) |
| Cardiovascular support n (%) | ||
| Inotropes | 20 (57%) | 14 (47%) |
| Fluid bolus | 23 (66%) | 19 (63%) |